GeoVax Labs, Inc. stock is down -25.45% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 31.03% of the previous 28 December’s closed higher than November. 100% of analysts rate it a buy.
GeoVax Labs, Inc. develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV) and malaria.